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Abstract 
Introduction:  
Currently there are approximately 1.2 million people in the United States living with HIV 
and it is estimated that 25.6% of HIV-positive adults suffer from depression. The purpose 
of this study is to examine the contribution of depression on substance use and 
medication adherence specifically among HIV-positive adult Georgians receiving 
medical care for HIV. 
Methods: 
Secondary data with a probability sample of 608 HIV-positive adults who took part in the 
2009-2012 Georgia Medical Monitoring Project (MMP) were analyzed. Descriptive 
analysis and multivariate logistic regression models were conducted to assess 
relationships between depression with current cigarette smoking, injection drug use, other 
non-injection drug use, and medication adherence, adjusting for sociodemographic 
covariates (age, gender, race, and education). All analyses accounted for non-response 
and complex sampling design and were performed using SAS 9.2 (Cary, NC).  
Results: 
Among HIV-positive adults in Georgia, approximately 9.2% met the criteria for major 
depression; 15.2% of women and 6.9% of men had major depression. Heterosexual adults 
also had a higher percentage of major depression (11.9%) compared to adults who 
identified as bisexual (8.3%) or homosexual (6.1%). Major depression was also highest 
among young adults (17.1%) and adults with high school diploma or GED (13.0%). 
Major depression was associated with a greater odds of current cigarette smoking (3.04; 
95% CI: 1.48, 6.23); injection drug use (5.62; 95% CI: 0.96, 32.81), and other non-
injection drug use (2.17; 95% CI: 1.10, 4.25), after adjusting for sociodemographic 
variables. Major depression was also associated with a greater odds of ART medication 
non-adherence, 2.52 (95% CI: 1.20, 5.28), after adjusting for gender.  
Conclusion: 
As previously found in the general population, we found significant associations between 
depression and smoking and other non-injection drug use among HIV-positive adults. 
Major depression was also associated with a greater odds of ART medication non-
adherence, which is also consistent with the literature. Because HIV-positive adults have 
ongoing encounters with healthcare providers, screening and treatment for depression and 
other co-morbid substance use is needed to reduce an additional health burden in this 
population. 
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CHAPTER I: Introduction 
1.1 Background 
 Approximately 1.2 million people within the United States are currently living 
with Human Immunodeficiency Virus (HIV), and nearly 14% are not aware of their HIV 
infection (“CDC - HIV/AIDS”). The CDC estimates 50,000 new HIV infections each 
year (“CDC - HIV/AIDS”). According to the Georgia Department of Public Health 
HIV/AIDS Epidemiology Section, approximately 50, 436 people were living with HIV in 
Georgia as of December 31, 2012 (The Georgia Department of Public Health Fact Sheet: 
HIV Surveillance, Georgia, 2012). Georgia has the sixth highest HIV prevalence among 
adults and adolescents in the United States, and Georgia ranked fourth highest in the 
United States for new HIV infections in 2011 (The Georgia Department of Public Health 
Fact Sheet: HIV Surveillance, Georgia, 2012). 
If left untreated, HIV leads to acquired immunodeficiency syndrome (AIDS). HIV 
impairs the immune system by destroying CD4 cells. HIV is classified into three stages 
which are measured by CD4 counts. Stage three is when CD4 levels are the lowest, 
classified as AIDS. Although there is no cure at this time, treatment with antiretroviral 
therapy (ART) is highly effective at improving the quality and longevity of life among 
people living with HIV. ART lowers a person’s viral load and decreases the risk of 
transmission (The Georgia Department of Public Health Fact Sheet: HIV Surveillance, 
Georgia, 2012).  
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Adults with HIV experience multiple comorbid social, behavioral, physical, and 
mental health problems. For example, adults with HIV may deal with stigma and 
discrimination, and this may lead to chronic stress and substance use. Adults with HIV 
also may engage in more risk taking behaviors such as unprotected sex or needle-sharing 
injection drug use, and because many persons may not know they are infected, risk taking 
behaviors by persons with HIV may further increase the likelihood of spreading the virus. 
 While individuals living with HIV are living longer lives compared to the era 
before ART, complications and barriers still exist linking and retaining individuals with 
HIV to treatment and care. Specific comorbidities are common to people living with 
HIV. Mental illness, specifically depression, disproportionately affects this population. 
The presence of depression among HIV-positive adults is strongly suspected to be a 
barrier to accessing and remaining in care.  
1.2 Purpose of the study 
 The purpose of this study is to examine the association of major depression with 
current cigarette smoking, injection drug use, other non-injection drug use, and 
medication adherence, among adults in Georgia receiving medical care for HIV infection 
using the Georgia Medical Monitoring Project Data, 2009-2012. 
1.3 Hypotheses 
The four null hypotheses will be tested using multivariate logistic regression: (1) Among 
adults residing in Georgia living with HIV, major depression will have no association 
with current cigarette smoking, (2) Among adults residing in Georgia living with HIV, 
major depression will have no association with injection drug use, (3) Among adults 
residing in Georgia living with HIV, major depression will have no association with other 
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non-injection drug use, and (4) Among adults residing in Georgia living with HIV, major 
depression will have no association with ART medication adherence.
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CHAPTER II: Literature Review 
2.1 Epidemiology of HIV 
 Approximately 1.2 million people within the United States are currently living 
with Human Immunodeficiency Virus (HIV) (“CDC - HIV/AIDS”). Currently, African 
Americans are most affected by HIV in the United States. African American’s rate of 
infection is nearly 8 times compared to whites (“CDC - HIV/AIDS”). African Americans 
also have a higher proportion of new HIV infections, a higher prevalence of HIV 
infections, and a higher proportion of persons ever diagnosed with AIDS (“CDC - 
HIV/AIDS”). An estimated 44% of all new HIV infections among individuals 13 or older 
were African Americans, and among those, an estimated 70% were men. More new HIV 
infections were among African American men who have sex with men, ages 13 to 24, 
than other men who have sex with men (“CDC - HIV/AIDS”).  
 In the United States, 75% of all adults living with HIV were men, and the 
majority of those individuals were men who have sex with men (“CDC - HIV/AIDS”). 
Among women, most new HIV infections are from heterosexual contact (“CDC - 
HIV/AIDS”). As with men, African American women are disproportionately affected by 
HIV compared to other races; nearly 64% of HIV-positive women are African American. 
Also, women overall are not receiving adequate care for their HIV in the United States. 
Only 45% of HIV-positive women were retained in care (“CDC - HIV/AIDS”). 
 Similar trends are observed in Georgia compared to national HIV epidemiology. 
According to the Georgia Department of Public Health HIV/AIDS Epidemiology 
Section, approximately 50, 436 people were living with HIV in Georgia as of December 
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31, 2012 (The Georgia Department of Public Health Fact Sheet: HIV Surveillance, 
Georgia, 2012). Georgia has the sixth highest HIV prevalence among adults and 
adolescents in the United States, and Georgia ranked fourth highest in the United States 
for new HIV infections in 2011 (The Georgia Department of Public Health Fact Sheet: 
HIV Surveillance, Georgia, 2012). Men account for 78% of new HIV infections, and 
55% of all new HIV infections were African American.  
2.2 Epidemiology of Depression among Adults in the U.S. Population 
 During 2009-2011, an annual average of 19.9% of adults had a mental illness, 
including individuals with depression, schizophrenia, and bipolar disorders (Centers for 
Disease Control and Prevention (CDC), 2013). Among these individuals, the highest 
proportion of mental illness was among adults ages 18 to 24 and among women. An 
estimated 23.4% (95% CI, 22.9-23.9) of women had a mental illness compared with 
16.1% (95% CI, 15.7-16.6) of men (Centers for Disease Control and Prevention (CDC), 
2013). The median state percentage of adults with any mental illness was 20.4%, and 
Georgia had a 17.2% percentage of adults with a mental illness (Centers for Disease 
Control and Prevention (CDC), 2013). A recent examination of NHANES 2009-2010 
revealed that the prevalence of depressive symptoms among adults ages 18 and older was 
25.7% (Wittayanukorn, Qian, & Hansen, 2014). Among the 25.7% experiencing 
depressive symptoms, 36.6% were classified as having moderate to severe depression 
(Wittayanukorn et al., 2014). Furthermore, among those classified as having moderate to 
severe depression, only 38.7% were receiving antidepressant medication or seeing a 
mental health professional (Wittayanukorn et al., 2014). 
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 Major depressive disorder, as defined by the Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition (DSM-IV), includes experiencing five or more 
depressive symptoms (American Psychiatric Association, 2000). These symptoms can 
include feeling sad or empty, diminished interest in activities, significant weight loss, 
insomnia or hypersomnia, psychomotor agitation, fatigue, feelings of worthlessness, and 
an inability to concentrate (American Psychiatric Association, 2013).  
 There are multiple scales and instruments currently used to assess depression 
among the adult population. The Patient Health Questionnaire (PHQ-9) is one such 
instrument, which has become an increasingly popular tool in surveillance systems to 
assess the 9 criteria for depression as defined by the DSM-IV (American Psychiatric 
Association, 2000; K. Kroenke, Spitzer, & Williams, 2001). Recently, a PHQ-8 became 
available that consisted of an 8-item version of the PHQ-9 (Kurt Kroenke et al., 2009). 
PHQ-8 has demonstrated strong validity and reliability as a measure to assess current 
depression (Kurt Kroenke et al., 2009). 
2.3 Depression among Adults living with HIV 
 Among HIV-infected individuals, depression is the most common 
neuropsychiatric disorder that affects these individuals (Nanni, Caruso, Mitchell, 
Meggiolaro, & Grassi, 2015). The prevalence of depression among HIV-infected 
individuals is anywhere between 18 and 81 percent (Arseniou, Arvaniti, & Samakouri, 
2014). Depression also disproportionately affects HIV-positive individuals compared to 
HIV-negative individuals (Bing et al., 2001). Using the National Medical Monitoring 
Project (MMP) and the Behavioral Risk Factor Surveillance System (BRFSS), the 
prevalence of any depression among HIV-positive adults in care was 25.6% (95% CI: 
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23.8%-27.4%) compared to 9.1% (95% CI: 8.9%-9.4%) of adults in the general 
population who had any depression (Do et al., 2014). An estimated 12.4% (95% CI: 
11.2%, 13.7%) of HIV-positive adults had major depression compared to 4.1% (95% CI: 
3.9%, 4.2%) who had major depression in the general population (Do et al., 2014). This 
estimate of 25.6% of HIV-positive adults with any depression is also higher than the 
estimated 19.9% of adults in the general population who had a mental illness (Centers for 
Disease Control and Prevention (CDC), 2013). Compared to the general population, HIV 
positive persons are between two and seven times more likely to be diagnosed with major 
depression (Hinkin, Castellon, Atkinson, & Goodkin, 2001; Do et al., 2014). Depression 
among people living with HIV is known to have an effect on several health outcomes and 
health behaviors (Arseniou et al., 2014).  
 The relationship between depression and HIV infection is complicated, and the 
directionality of causation is often unclear. Depression does not only frequently occur 
after HIV diagnosis, but depression can be a risk factor for HIV transmission (Nanni et 
al., 2015). Adults with severe mental illness (SMI), including those with depression, are 
more likely to engage in risky sexual behavior or use injection drugs, therefore increasing 
HIV transmission risk (Meade & Sikkema, 2005). In the study by Do et al., adults who 
engaged in one or more HIV risk behaviors had a depression prevalence twice the 
depression prevalence of adults who did not engage in HIV risk behaviors (2014).  
Biological Etiologies of Depression among persons living with HIV 
 Depression also frequently occurs after HIV diagnosis. Depression within the 
HIV-positive population has several etiologies, including biological and psychosocial 
factors (Arseniou et al., 2014). HIV infection may play a role in secondary depression by 
8 
 
 
 
altering biological elements within the brain, leading to depression. One indication that 
the HIV virus has infected the central nervous system is the presence of neurocognitive 
defects, which also may potentially cause depression (Gibbie et al., 2006). HIV infection 
has been linked to alterations of neural networks and white matter structure, alterations of 
brain morphology, somatostatin dysregulation, and tryptophan degradation (Gibbie et al., 
2006). Several studies have examined brain structure alterations among HIV-negative 
individuals with major depression, and they have found several brain structures actually 
morph over time (Milak et al., 2005; Sheline, 2000). These certain brain structures, 
including basal ganglia, orbitofrontal cortex, and neural networks, are also vulnerable to 
HIV infection, which may cause secondary depression (Arseniou et al., 2014). Long-term 
studies are needed to further examine this relationship, but there is evidence linking HIV 
infection and depression within the brain structures.  
 Another biological mechanism that has been hypothesized as linking HIV 
infection to depression is hypothalamus-pituitary-thyroid (HPT) dysfunction (Arseniou et 
al., 2014). HPT dysfunction, among the HIV-negative population, is known to cause 
depression, along with mood disorders and dementia. HIV infection of the CNS may alter 
hypothalamus and thyroid communication; therefore, HIV infection of the CNS may 
cause depression through this mechanism (Langford, Baron, Joy, Del Valle, & Shack, 
2011).  
Psychosocial Etiologies of Depression among persons living with HIV 
 Apart from the biological factors explaining depression diagnoses post-HIV 
infection, psychosocial factors among HIV-positive adults also contribute to the 
depression etiology in this population. Among the general population, people who are 
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newly diagnosed with a chronic illness or disease exhibit elevated levels of depression 
(DeJean, Giacomini, Vanstone, & Brundisini, 2013). Among HIV positive individuals, 
changes in social support structure and body image, perceived stigma, and occupational 
disability contribute to an increase risk of depression (Olatunji, Mimiaga, O’Cleirigh, & 
Safren, 2006). Among a study assessing the emotions of newly diagnosed men and 
women in the San Francisco area, a qualitative analysis revealed several common themes 
about initial diagnosis, including concerns about dying, stigma, and a threat to identity 
(Moskowitz, Wrubel, Hult, Maurer, & Acree, 2013).   
Depression’s Impact on the Progression of HIV  
 Depression is not only harmful to individuals living with HIV and their sense of 
well-being, but one study revealed depressive symptoms were associated with a quicker 
development of an AIDS condition compared to individuals without depressive 
symptoms (J. Leserman et al., 2002). This rapid progression can be due to a variety of 
factors, including individuals with depressive symptoms adhering less to HIV medication 
regimen than individuals without depressive symptoms (Soller et al., 2011). Chronic 
depression, as well as stressful events and trauma, may negatively influence disease 
progression by decreasing CD4 T lymphocytes and increasing risk for mortality 
(Leserman, 2003; Leserman, 2008). The extent of this relationship of depression to 
biomarkers still needs to be explored; depression may influence psychosocial and 
behavioral risk factors, which subsequently influence an increase in viral load or decrease 
in CD4 T lymphocytes (Schuster, Bornovalova, & Hunt, 2012).  
 Early studies revealed depression has a substantial influence on the immune 
system. In addition to the influences of depression on the progression of HIV disease, this 
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is further worsened by depression’s negative influence on the production of cytotoxic 
lymphocytes (Herbert & Cohen, 1993). Hyperactivity of the HPA axis, which results 
from major depression, increases glucocorticoid circulation (Pariante & Lightman, 2008). 
Glucocorticoids have an effect on the production of interleukins and interferons, which 
have a direct impact on lymphocytes’ mechanism of fighting infectious agents (Schuster 
et al., 2012).  
 In addition to these studies, other researchers sought to evaluate depression’s 
effect on the immune system in patients on antiretroviral therapy. A small study in Italy 
revealed a significant difference in the number of natural killer cells between depressed 
individuals and non-depressed individuals (Alciati, Gallo, Monforte, Brambilla, & 
Mellado, 2007). These participants were all receiving antiretroviral therapy.   
2.4 Depression and Cigarette Smoking among Adults living with HIV 
The association between depression and cigarette smoking among the general population 
 Among the general United States adult population, a strong relationship between 
mental illness and tobacco use exists in the general U.S. adult population and also across 
US states (Dube et al., 2009; McClave et al., 2009). During 2009-2011, a yearly average 
of 19.9% of adults ages 18 and older were living with a mental illness, and among these 
adults, 36.1% were current smokers (Centers for Disease Control and Prevention (CDC), 
2013). Among the general adult population ages 18 and older, 21.4% of adults are current 
smokers, substantially lower than the smoking prevalence among those living with a 
mental illness (Centers for Disease Control and Prevention (CDC), 2013). Among 
Georgians, an estimated 24% (95% CI, 18.8-30.1) of adults with a mental illness smoke. 
Potential reasons for the association between mental illness and tobacco use is the 
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psychoactive properties of nicotine, which may help to ameliorate negative affective 
states that are symptoms of many types of mental illnesses, including major depression 
(McClave, McKnight-Eily, Davis, & Dube, 2010; Strine et al., 2012; Trosclair & Dube, 
2010).  
Depression and cigarette smoking among persons living with HIV 
 While mental illnesses, including depression, have a known association with 
cigarette smoking, the general adult population living with HIV also experience a higher 
smoking prevalence compared to the general adult population in the United States 
(Browning, Wewers, Ferketich, & Diaz, 2013; Centers for Disease Control and 
Prevention (CDC),"BRFSS,” 2013). Studies have reported smoking prevalence in the 
range of 40-70% among persons living with HIV, compared to the general population 
smoking prevalence of 21.4% (Centers for Disease Control and Prevention (CDC), 2013). 
In 2013, the Behavioral Risk Factor Surveillance System (BRFSS) estimated only 17.8% 
of adults are current smokers, a decrease from the previous estimate of 21.4% (Centers 
for Disease Control and Prevention (CDC),"BRFSS,” 2013).  Mdodo et al, 2015 
examined smoking prevalence and quit ratios among HIV adults in care who participated 
in the Medical Monitoring Project compared to adults who participated in the National 
Health Interview Survey in 2009 (2015). Smoking prevalence among adults was 42.4% 
(95% CI, 39.7% to 45.1%) compared to 20.6% of adults in the general population 
(Mdodo et al., 2015). Adults living with HIV were nearly twice as likely to smoke, and 
less likely to quit smoking (quit ratio, 32.4% vs. 51.7%) (Mdodo et al., 2015). Adults 
living with HIV are disproportionately affected by cigarette smoking compared to the 
general adult population.  
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 Depression may be a factor in the high cigarette smoking prevalence observed in 
people living with HIV (Browning et al., 2013). Due to the high proportion of depression 
among HIV-positive individuals, smoking may in fact help to mitigate the effects of 
depression, as seen in the general adult population (Burkhalter, Springer, Chhabra, 
Ostroff, & Rapkin, 2005). HIV-positive individuals that currently smoke also have lower 
quit rates compared to the general adult population, and a high prevalence of depression 
may impact quit attempts (Burkhalter et al., 2005).  
 Shuter, Bernstein, and Moadel examined smoking behaviors and beliefs among 
persons living with HIV (2012). These individuals were receiving care, and most of the 
individuals explained that cigarette smoking helped them cope with anger, depression, or 
anxiety (Shuter et al., 2012). Among these participants, 73.3% stated they were currently 
depressed or experienced depression in the past (Shuter et al., 2012).   
The increased burden of cigarette smoking among persons living with HIV 
 Cigarette smoking increases risk for diseases for HIV-positive smokers, including 
cardiovascular disease, pneumonia, lung cancer, and liver cancer (Helleberg et al., 2013). 
HIV-positive smokers are more susceptible to develop chronic obstructive pulmonary 
disorder (COPD) compared to smokers in the general population (Crothers et al., 2006). 
One study revealed liver cancer risk is synergistically increased by HIV infection and 
current tobacco use (Helleberg et al., 2013).  The authors also reported a substantial 
increase in mortality among HIV-positive smokers compared to HIV-infected non-
smokers (Helleberg et al., 2013). In another study, Helleberg, et al, examined associations 
between smoking and mortality among individuals in care with more than one year after 
initiation on antiretroviral therapy (ART), excluding injection drug users (Helleberg et 
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al., 2015). The mortality rate ratio (MRR) which compared HIV-infected smokers with 
HIV-infected nonsmokers was 1.94 (95% CI 1.56-2.41). HIV-positive smokers also 
experienced a higher mortality from cardiovascular disease [MRR 6.28 (95% CI 2.19-
18.0)] (Helleberg et al., 2015). The loss life-years associated with smoking was 7.9 (95% 
CI 7.1-8.7) (Helleberg et al., 2015).  
2.5 Depression and Substance Use among Adults living with HIV 
 Previous research has demonstrated a relationship between depression and 
substance use in persons living with HIV. Studies have estimated between 10% and 28% 
of persons living with HIV have co-occurring substance use disorders and mental illness 
disorders, including depression (Burnam et al., 2001; Dausey & Desai, 2003). A national 
study that utilized a probability sample of HIV-positive individuals in care revealed that 
drug dependence was independently associated with a number of factors, including 
screening positive for a psychiatric disorder, including depression (Bing et al., 2001). 
Berger-Greenstein et al. estimated a 72% prevalence of depression among HIV-positive 
substance users in a low-income, urban setting (2007). Depression and substance use 
disorders are also related to low medication adherence, essentially creating a complicated 
mechanism of disease progression (Magidson et al., 2014).  
  Researchers have also found that depressive symptoms are associated with an 
increase in risky behaviors, which have an even larger impact on HIV-positive substance 
users, particularly injection-drug users (Johnson, Rabkin, Lipsitz, Williams, & Remien, 
1999). Depressive symptoms have been related to an increase in needle-sharing, which 
increases both the risk of transmissibility of HIV as well as a new infection of a different 
strain of HIV to those already infected (Johnson et al., 1999; Berger-Greenstein et al., 
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2007). Persons who are infected with more than one strain of HIV have an increased 
probability of experiencing resistance to antiretroviral medications (Berger-Greenstein et 
al., 2007). 
 Although the relationship between depression and substance use has been 
explored among persons living with HIV, few articles examine the relationship between 
depression and use of specific drugs, especially non-injection drugs, among persons 
living with HIV in care. A study which examined co-occurring substance use disorders 
with psychological distress found the strongest relationship among opioid users 
(McCabe, Feaster, & Mitrani, 2014). Opioid users had three times the odds of having co-
occurring psychological distress (OR=2.75, p=0.035) (McCabe et al., 2014). This article 
also assessed relationships between psychological distress and use of other substances, 
including cannabis, alcohol, and sedatives; however, these relationships were not 
statistically significant (McCabe et al., 2014).  
2.6 Depression and HIV Medication Adherence 
Depression has been linked to a decrease in HIV medication adherence in more 
than 95 studies (Gonzalez, Batchelder, Psaros, & Safren, 2011). This meta-analytic 
review found that across 95 independent samples depression was significantly (P<0.01) 
related to medication non-adherence (r=0.19; 95% CI 0.14-0.25) (Gonzalez et al., 2011). 
However, contradicting results were found in a study assessing medication adherence 
among HIV-positive substance users with a mental illness, including those with 
depression (Berger-Greenstein et al., 2007). The participants were actively receiving care 
for HIV, and 72.9% of participants had major depression disorder (Berger-Greenstein et 
al., 2007). The researchers found that participants who reported a high number of 
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depression symptoms were also likely to report a high rate of medication adherence 
compared to individuals reporting a smaller number of depression symptoms (Berger-
Greenstein et al., 2007). The authors reasoned that depressed individuals are more likely 
to be concerned with longevity of life and their health, and they are more likely to take 
their medications. They also proposed that medication adherence could have been falsely 
reported by these individuals, possibly due to their depression interfering with memory 
recall or social desirability bias (Berger-Greenstein et al., 2007).  
Although many studies have assessed the relationship of depression to HIV 
medication adherence, articles have revealed inconsistent results. Few articles also 
explore the relationship between depression and medication adherence among individuals 
receiving continuous care for HIV (Berger-Greenstein et al., 2007). Other researchers 
have sought to examine the relationships between depression, non-medication adherence, 
and other variables.  
Medication adherence is measured in a variety of ways. Although medication 
adherence is measured primarily by self-reported questionnaires or interviews, 
medication adherence can also be measured by viral load (Bonner, Mezochow, Roberts, 
Ford, & Cohn, 2013). Most HIV-positive individuals who are adhering to antiretroviral 
medications are virally suppressed.  
2.7 Summary of Literature Review and Gaps 
 Individuals living with HIV and co-morbid depression experience more adverse 
health behaviors, such as medication non-adherence, current cigarette smoking, and 
substance use, compared to individuals living without depression. Untreated depression 
negatively affects multi-dimensional aspects of life for persons living with HIV. 
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Abstaining from substance use and cigarette smoking behaviors has been shown to 
prolong life for this population. Furthermore, adhering to ART medication promotes 
healthier, longer lives while substantially decreasing the risk of HIV transmission. 
However, these important behaviors are negatively impacted by depression. Since 
depression has such a high prevalence in this population compared with the general 
population, identifying and treating depression has enormous implications for persons 
living with HIV.  
 Although a substantial amount of literature exists around depression among 
persons living with HIV, few studies have consistently evaluated individuals living with 
HIV who are currently receiving medical care. By analyzing Medical Monitoring Project 
participants in Georgia, this study can provide a unique perspective of the association of 
depression on certain health behaviors among individuals currently receiving medical 
care for HIV. Most studies reviewed have examined the relationship between depression 
and adverse health outcomes; however, no studies to date have assessed the relationship 
between depression and adverse health outcomes among HIV-positive adults in Georgia 
receiving care. The results will inform public health professionals and healthcare 
providers on the importance of screening and treatment of depression among this 
population.  
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Abstract 
Introduction:  
Currently there are approximately 1.2 million people in the United States living with HIV 
and it is estimated that 25.6% of HIV-positive adults suffer from depression. The purpose 
of this study is to examine the contribution of depression on substance use and 
medication adherence among HIV-positive adults receiving medical care for HIV. 
Methods: 
Secondary data with a probability sample of 608 HIV-positive adults who took part in the 
2009-2012 Georgia Medical Monitoring Project (MMP) were analyzed. Descriptive 
analysis and multivariate logistic regression models were conducted to assess 
relationships between depression with current cigarette smoking, injection drug use, other 
non-injection drug use, and medication adherence, adjusting for sociodemographic 
covariates (age, gender, race, and education). All analyses accounted for non-response 
and complex sampling design. 
Results: 
Among HIV-positive adults in Georgia, approximately 9.2% met the criteria for major 
depression; 15.2% of women and 6.9% of men had major depression. Heterosexual adults 
also had a higher percentage of major depression (11.9%) compared to adults who 
identified as bisexual (8.3%) or homosexual (6.1%). Major depression was also highest 
among young adults (17.1%) and adults with high school diploma or GED (13.0%). 
Major depression was associated with a greater odds of current cigarette smoking (3.04; 
95% CI: 1.48, 6.23); injection drug use (5.62; 95% CI: 0.96, 32.81), and other non-
injection drug use (2.17; 95% CI: 1.10, 4.25), after adjusting for sociodemographic 
variables. Major depression was also associated with a greater odds of ART medication 
non-adherence, 2.52 (95% CI: 1.20, 5.28).  
Conclusion: 
As previously found in the general population, we found significant associations between 
depression and smoking and other non-injection drug use among HIV-positive adults. 
Because HIV-positive adults have ongoing encounters with healthcare providers, 
screening and treatment for depression and other co-morbid substance use is needed to 
reduce an additional health burden in this population. 
 
Key Words: Depression, substance use, cigarette smoking, antiretroviral medication 
adherence, HIV, Behavior 
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Introduction 
 Approximately 1.2 million people within the United States are currently living 
with Human Immunodeficiency Virus (HIV) (“CDC - HIV/AIDS”). According to the 
Georgia Department of Public Health HIV/AIDS Epidemiology Section, approximately 
50, 436 people were living with HIV in Georgia as of December 31, 2012 (The Georgia 
Department of Public Health Fact Sheet: HIV Surveillance, Georgia, 2012). Georgia has 
the sixth highest HIV prevalence among adults and adolescents in the United States, and 
Georgia ranked fourth highest in the United States for new HIV infections in 2011 (The 
Georgia Department of Public Health Fact Sheet: HIV Surveillance, Georgia, 2012). 
 While individuals living with HIV are living longer lives compared to the era 
before antiretroviral therapy (ART), complications and barriers still exist linking and 
retaining individuals with HIV to treatment and care. Specific comorbidities are common 
to people living with HIV. Mental illness, specifically depression, disproportionately 
affects this population, and depression is strongly suspected to be one barrier to accessing 
and remaining in care. Among HIV-infected individuals, depression is the most common 
neuropsychiatric disorder that affects these individuals (Nanni, Caruso, Mitchell, 
Meggiolaro, & Grassi, 2015). Compared to the general population, HIV positive persons 
are between two and seven times more likely to be diagnosed with major depression 
(Hinkin, Castellon, Atkinson, & Goodkin, 2001; Do et al., 2014). 
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Depression among people living with HIV is known to have an effect on several 
health outcomes and health behaviors, including medication adherence (Arseniou, 
Arvaniti, & Samakouri, 2014). Depression has been linked to a decrease in HIV 
medication adherence in more than 95 studies (Gonzalez, Batchelder, Psaros, & Safren, 
2011).  However, Berger-Greenstein et al found that participants who reported a high 
number of depression symptoms were also likely to report a high rate of medication 
adherence compared to individuals reporting a smaller number of depression symptoms 
(2007).  
 Other adverse health behaviors, including cigarette smoking and substance use, 
have also been associated with depression (McClave, McKnight-Eily, Davis, & Dube, 
2010; Strine et al., 2012; Trosclair & Dube, 2010). For example, among persons with any 
mental illness, 36.1% are current smokers, substantially higher than the general 
population  (CDC, 2013). The psychoactive properties of nicotine in tobacco, may be 
used to ease symptoms of mental illness, including major depression (McClave et al., 
2010; Strine et al., 2012; Trosclair & Dube, 2010). Due to the high proportion of 
depression among HIV-positive individuals, the nicotine from smoking cigarettes may in 
fact help to mitigate the effects of depression, as seen in the general adult population 
(Burkhalter, Springer, Chhabra, Ostroff, & Rapkin, 2005). Adults living with HIV are 
nearly twice as likely to smoke, and less likely to quit smoking (quit ratio, 32.4% vs. 
51.7%) (Mdodo et al., 2015). Substance use also has demonstrated an association with 
depression, among both the general population and those with HIV. Studies have 
estimated between 10% and 28% of persons living with HIV have co-occurring substance 
use disorders and mental illness disorders, including depression (Burnam et al., 2001; 
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Dausey & Desai, 2003). Depression and substance use disorders are also related to low 
medication adherence, essentially creating a complicated mechanism of disease 
progression (Magidson et al., 2014). 
 The purpose of this study is to examine the excess burden of depression on 
current cigarette use, injection drug use, non-injection drug use, and ART medication 
adherence, among adult Georgians receiving medical care for HIV infection using the 
Georgia Medical Monitoring Project Data, 2009-2012. By analyzing depression’s 
association with these health behaviors, individuals involved in care of HIV-positive 
persons can determine the importance of screening and treating depression. 
Methods 
Sample and Data Source 
 The Georgia Medical Monitoring Project (MMP) is a surveillance system that 
collects data on behavioral and clinical aspects of persons living with HIV who are 
currently receiving medical care (“Georgia Medical Monitoring Project (MMP) | Georgia 
Department of Public Health”). For the purposes of the present study, a secondary 
analysis was conducted using 2009, 2010, 2011, and 2012 aggregate MMP data. 
Institutional Review Board at Georgia State University determined the study to be 
exempt. 
MMP consists of a three-stage, probability sampling method, and Georgia is one 
of 26 states and cities across the United States to participate (“Georgia Medical 
Monitoring Project (MMP) | Georgia Department of Public Health”). MMP project areas 
are estimated to include over 80% of the total HIV/AIDS patients in the United States. 
Interviews are conducted either face-to-face or via phone to ascertain behavioral 
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information, and medical record abstractions are used to obtain clinical information. To 
be eligible to participate, individuals were required to be HIV-positive, 18 years of age or 
older at the time of the interview, and actively receiving medical care for HIV. Data from 
the Georgia MMP are weighted to produce a representative sample of all adult Georgians 
receiving medical care for HIV (McNaghten et al., 2007; Blair et al., 2011; Frankel et al., 
2012). Once facilities are selected and agree to participate, patient lists are generated and 
a random sample of 400 Georgia patients are randomly selected.  Patient and facility 
response rates are combined into one response rate to report for each year of MMP. For 
2009, the combined response rate was 27.39%, the combined response rate for 2010 was 
17.58%, the combined response rate for 2011 was 23.23%, and the combined response 
rate for 2012 was 34.71%.   
Measures 
Independent Variables 
 Depression is measured in MMP using the Eight-Item Patient Health 
Questionnaire (PHQ-8) (Kurt Kroenke et al., 2009; K. Kroenke, Spitzer, & Williams, 
2001). The PHQ-8 was adopted from the PHQ-9, which assesses the nine criteria 
associated with depression as defined by the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV) (American Psychiatric Association, 2000). The ninth 
item that was omitted from the PHQ-8 assesses suicidal ideations, and due to the majority 
of interviewers not being trained mental health providers, this item was removed to create 
a more widely used tool, the PHQ-8 (Kurt Kroenke et al., 2009; K. Kroenke et al., 2001). 
The PHQ-8 has demonstrated to be closely comparable to the PHQ-9 (Kurt Kroenke, 
Spitzer, Williams, & Löwe, 2010). According to a systematic review of the PHQ-9, the 
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measure has demonstrated internal reliability or 0.86 to 0.89 and external reliability of 
0.84 in identifying depression in both clinical settings and general population settings 
(Kurt Kroenke et al., 2010).  
 Methods used to identify individuals with major depression are consistent with 
the DSM-IV criteria (American Psychiatric Association, 2000) as well as methods used 
to identify major depression in a national MMP study (Do et al., 2014). The PHQ-8 asks 
if the individuals experienced certain symptoms within the last two weeks. Individuals 
were considered to have major depression if the individual had five out of the eight 
symptoms “more than half the days” out of the last two weeks, and the individual 
answered “more than half the days” in response to at least one of the first two questions: 
1) “Little pleasure in doing things”, 2) “Feeling down, depressed, or hopeless” (Kurt 
Kroenke et al., 2009; Do et al., 2014).  
Dependent Variables 
 Injection drug use  
 Participants who responded that they had used injection drugs in the past 12 
months were defined injection drug use. The interviewer explains that injection drugs for 
non-medical purposes include using drugs with a needle, “either by mainlining, skin 
popping, or muscling.” The participant can identify which drug (heroin, cocaine, heroin 
and cocaine together, crack, methamphetamine, amphetamines, oxycontin, steroids or 
hormones, or any other drug) and how often the individual used the drug. 
Other non-injection drug use  
Participants who responded that they had used other non-injection drugs in the 
past month  (methamphetamines, amphetamines or stimulants, crack, cocaine, downers 
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such as Valium, Ativan, Xanax, painkillers such as Oxycontin, Vicodin, Percocet, 
hallucinogens such as LSD, or mushrooms, and other drugs like ecstasy, heroin or opium, 
marijuana, amyl nitrate, GHB, or ketamine) and how often they used the drug during the 
past 12 months (daily, weekly, monthly, less than monthly, never, refused, or don’t 
know).  
Current Cigarette Smoking 
 For the descriptive analysis, current cigarette smoking was categorized as current 
cigarette smoker, former cigarette smoker, and never smoker. Cigarette smoking was 
assessed using the CDC criteria used to assess current smoker status (“CDC Disability 
and Health Data System (DHDS)”). Individuals were defined as current smokers if the 
individual answered “Yes” to “Have you smoked at least 100 cigarettes in your entire 
life?” and if the individual answers “Daily,” “Weekly,” or “Monthly” in response to 
“How often do you smoke cigarettes now?” (“CDC Disability and Health Data System 
(DHDS)”). To meet the criteria of a former cigarette smoker, participants answered 
“Yes” to “Have you smoked at least 100 cigarettes in your entire life?” and “Never” to 
“How often do you smoke cigarettes now?” Never smokers were classified if participants 
answered “No” to “Have you smoked at least 100 cigarettes in your entire life?”  
Individuals were classified as current smokers or non-smokers for the purpose of 
the logistic regression analysis. Current smokers were classified using the same 
methodology as the descriptive analysis, and former smokers were categorized with never 
smokers into the non-smoker category.  
 ART Medication Adherence 
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 ART medication adherence was assessed using several questions. Adults who 
reported ever taking any antiretroviral medicines were included in the analysis. 
Participants who responded they were not currently taking antiretroviral medicines due to 
reasons other than doctor advisement, but had taken antiretroviral medicines in the past, 
were classified as non-adherent. If participants reported their antiretroviral medicines 
consisted of special instructions, such as taking medication with food or with plenty of 
fluids, and they reported following those instructions “Never,” “Rarely,” or “About half 
of the time,” they were classified as non-adherent. Participants who reported “Most of the 
time” or “Always” regarding following their instructions were classified as adherent. 
Also, if participants reported “Never,” “Rarely,” or “About half of the time,” to specific 
scheduling instructions for ART medications in the past 3 days, they were classified as 
non-adherent. Participants were classified as adherent if they reported following their 
scheduling instructions “Most of the time” or “Always.” Furthermore, if individuals 
reported missing their ART medications in the past week, 1-2 weeks ago, or 3-4 weeks 
ago, the participants were classified as non-adherent. If the participant reported the last 
time they missed their ART medication as 1-3 months ago, more than 3 months ago, or 
reported never skipping medications, they remained classified as adherent.   
 Drug holidays were also taken into consideration in assessing for medication 
adherence. Participants who responded “Yes” to the question, “Have you ever 
purposefully taken a ‘drug holiday’ from your antiretroviral medicines that wasn’t 
recommended by your doctor?” were classified as non-adherent, whereas participants 
who responded “No” were classified as adherent.  
35 
 
 
 
 Participants were excluded from the medication adherence analysis if they were 
never prescribed antiretroviral medicines due to their doctor’s recommendations or if 
they had never taken antiretroviral medicines. Participants were also excluded from the 
analysis if they reported having taken ART medicines in the past, were not currently 
taking ART medicines, but reported participating in an HIV clinical trial. Individuals who 
refused to answer or did not know if they were taking antiretroviral medicines were also 
excluded.   
Statistical Analyses 
 All statistical analyses were conducted using SAS 9.2 (SAS Institute, Inc., Cary, 
NC). Demographic variables between individuals with major depression and individuals 
without major depression were ascertained. All analyses accounted for the complex 
survey design and included weights, cluster and stratum variables. Multivariate logistic 
regression was conducted to assess associations between depression and dependent 
variables using procedures which accounted for complex sampling design. Logistic 
regression took into account various confounders based upon bivariate analyses of 
confounders in this dataset and previously documented confounders in the literature.  
Results 
 Demographic characteristics (Table 1) displayed differences among adults with 
major depression and those without major depression. The overall total weighted 
percentage of adults with major depression, 9.2% (95% CI: 6.8%, 11.7%), were similar to 
findings in a national MMP study, which found 12.4% (95% CI: 11.2%, 13.7%) of adults 
had major depression (Do et al., 2014). A greater percentage of females, 15.2%, were 
classified as having major depression (95% CI: 8.8%, 21.6%) compared to 6.9% of males 
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(95% CI: 4.6%, 9.1%). An estimated 11.9% (95% CI: 7.8%, 16.1%) of heterosexuals 
classified as having major depression, a higher percentage than those who identified as 
bisexual, 8.3% (95% CI: 2.2%, 14.4%), or homosexual, gay, or lesbian, 6.1% (95% CI: 
3.0%, 9.2%). A higher proportion of individuals whose highest education achieved was a 
high school education or GED met the criteria for major depression, 13.0% (95% CI: 
8.2%, 17.8%), compared to individuals with a higher level of education.  
 Adults who reported non-adherence to ART medication had a higher percentage 
of major depression, 20.8% (95% CI: 8.8%, 32.8%) compared to adults who reported 
adherence to ART medication, 8.2% (95% CI: 5.8%, 10.6%). Among all participants, 
9.7% (95% CI: 7.1%, 12.3%) met the criteria for non-adherence to ART medication. 
Among those who reported not currently taking antiretroviral medicines, reported reasons 
for non-adherence included due to doctor advisement or delay, 24.7% (95% CI: 10.1%, 
39.2%), due to side effects, 22.4% (95% CI: 9.4%, 35.4%), worried about ability to 
adhere, 7.4% (95% CI: 3.8%, 11.0%), or due to money or insurance issues, 26.4% (95% 
CI: 11.9%, 40.8%). As previously mentioned, participants who reported non-adherence 
due to doctor advisement to delay or stop treatment were excluded from the analysis. 
Logistic regression analyses (Table 2) examined the associations between ART 
medication adherence and major depression. After adjusting for gender, major depression 
was associated with a higher odds of non-adherence to medication, 2.52 (1.20, 5.28), 
compared to adults without major depression.  
 A higher percentage of current cigarette smokers had major depression, 16.1% 
(95% CI: 11.1%, 21.0%), compared to former cigarette smokers, 4.4% (95% CI: 0.5%, 
8.4%), and non-smokers, 5.9% (95% CI: 2.7%, 9.2%). Multivariate logistic regression 
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analyses compared current smokers to non-smokers. After adjusting for age, gender, race, 
and education, the odds of current cigarette smoking among individuals with major 
depression was 3.04 (95% CI: 1.48, 6.23) times the odds of current cigarette smoking 
among individuals without major depression.  
 Injection drug users had a much higher percentage of adults with major 
depression, 28.2% (95% CI: 2.4%, 54.0%) compared to non-injection drug users, 9.0% 
(95% CI: 6.5%-11.5%). However, due to the small sample size of unweighted individuals 
with major depression, the confidence interval is unstable. The adjusted odds ratio for 
persons with major depression and the association of injection drug use was 5.62 (95% 
CI: 0.96, 32.81). Both the injection drug odds ratio and the non-injection drug odds ratio 
were adjusted for age, gender, race, and education. Non-injection drug users also had a 
similar distribution of individuals with major depression as injection drug users. Among 
non-injection drug users, 14.2% (95% CI: 8.3%, 20.1%) had major depression compared 
to 7.7% (95% CI: 5.0%, 10.5%) of those who did not use non-injection drugs who had 
major depression. The adjusted odds ratio for non-injection drug use and major 
depression was 2.17 (95% CI: 1.10, 4.25).  
Discussion 
 Adults with major depression were more likely to report current cigarette 
smoking,  non-injection drug use in the past 12 months, and ART medication non-
adherence compared with individuals without major depression. Even after adjusting for 
potential confounders, these relationships were significant. Although injection drug users 
had a wide confidence interval and was not statistically significant, a larger raw sample 
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size would likely yield a significant relationship between major depression and injection 
drug use.  
  The association of depression and medication non-adherence is one that has been 
found in numerous studies, including a recent meta-analysis of 95 studies which showed 
a positive relationship between depression and medication non-adherence (Gonzalez, 
Batchelder, Psaros, & Safren, 2011). While we examined non-adherence through a 
multitude of self-reported measures, the association of depression and medication 
adherence could also be explored using viral load. Although the literature has 
demonstrated self-reported medication adherence and viral load are both consistent at 
operationalizing medication adherence, viral load suppression would be able to reveal 
who is virally suppressed and therefore medication adherent. Also, viral load levels could 
be longitudinally studied comparing adults with and without depression to examine if a 
difference exists with regards to change in viral loads over time, which would also reveal 
which adults remain in care. Furthermore, in this questionnaire, adults could report 
reasons why they are not currently taking antiretroviral medicines or why they haven’t 
ever taken antiretroviral medicines. While “feeling down or depressed” was an option as 
a reason for non-adherence, this was not selected by any participants.  
 The associations with injection and non-injection drugs are commonly found in 
the literature among the general population, as well as in adults living with HIV. Self-
reported drug use is likely under reported, and the prevalence of injection and non-
injection drug use is likely higher. Adults who are not in care may have an even higher 
prevalence of injection and non-injection drug use.  
Limitations 
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 Several limitations should be noted in our study. Due to the small sample of 
transgender persons, this gender category was excluded from logistic regression analyses 
(unweighted n=4, weighted n=159). Future studies should include larger sample sizes of 
transgender persons when examining the relationship between depression and behaviors, 
especially as this is a group that experiences health disparities, even among HIV-positive 
persons.  
 All measures examined were self-reported, which introduces the possibility of 
recall bias and potentially social desirability bias, especially with assessing previous drug 
use. As previously mentioned, injection drug users composed a small sample size 
(unweighted n= 8, weighted n=274). This is likely an underestimate of the true parameter 
of injection drug use. Future studies that include larger samples of HIV-positive persons 
would likely solve this issue. Also, obtaining medical histories or medical chart 
abstractions regarding previous injection drug use within the past 12 months could also 
be a more accurate estimate of injection drug use, as opposed to the self-reported 
measure.  
 Medication adherence analyses excluded individuals who had never taken 
antiretroviral medicines and individuals whose doctors delayed antiretroviral treatment 
due to CDC guidelines and recommendations for antiretroviral medicines prior to 2012. 
Since the guidelines post 2012 include recommending all persons living with HIV to be 
prescribed antiretroviral medicines, the effects of this policy may take a few years to be 
evident. Evaluating the association between medication adherence and major depression 
after this guideline change would be of interest.   
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 The MMP questionnaire does not assess whether or not the individual is taking 
medication for depression. By knowing whether or not an individual is taking 
antidepressants, analyses could be conducted on those with untreated depression. Persons 
with untreated depression experience more adverse health outcomes than those with 
treated depression. Associations of treated depression and medication adherence could be 
examined to evaluate if a difference exists compared to associations of untreated 
depression and medication adherence in this population of Georgians to evaluate if these 
associations are consistent with the literature.  
Lastly, the burden of depression among HIV-positive adults currently receiving 
care may underestimate the overall burden of depression among HIV-positive adults. 
Those seeking medical care may be more health-conscious. These individuals may also 
have less adverse health behaviors than the general HIV-positive population in the United 
States.   
Implications and Recommendations 
 The associations of depression with these health behaviors have enormous 
implications for depression treatment and screening for HIV-positive persons. Guidelines 
do exist for HIV specific care providers that take into account screening and treatment of 
depression (Aberg et al., 2009). Screening for depression has not been consistently 
implemented in HIV care provider settings, although recommended as part of HIV 
medical care guidelines (Shacham et al., 2009). Shacham et al demonstrated the PHQ-9 
as a feasible screening tool for HIV care providers (2009).  
 Smoking cessation programs for individuals with HIV should also address 
potential depression. Tobacco use and cigarette smoking has additional implications for 
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HIV-positive individuals, including increasing risks for cardiovascular disease, 
pneumonia, lung cancer, and liver cancer (Helleberg et al., 2013). Studies have 
demonstrated a substantial increase in mortality among smokers living with HIV, more 
than smoking or HIV alone (Helleberg et al., 2013). HIV providers and infectious disease 
providers need to recognize the importance of tobacco cessation within this population. 
Shuter, Bernstein, et al. examined smoking behaviors among people living with HIV, and 
83% of participants revealed their primary care provider discussed smoking cessation 
with them (2012). However, only 32.8% were referred to a quit line and 5.3% were 
referred to a smoking cessation program (Shuter et al., 2012). 
 A recent review assessed tobacco cessation programs among HIV-positive 
persons (Moscou-Jackson, Commodore-Mensah, Farley, & DiGiacomo, 2014). 
Interventions which incorporated cell phone cessation strategies were the most successful 
at smoking cessation rates (Vidrine, Arduino, Lazev, & Gritz, 2006; Vidrine, Marks, 
Arduino, & Gritz, 2012). The review concluded that the most successful interventions 
were adjusted to address specific needs of people living with HIV (Moscou-Jackson et 
al., 2014). Also, interventions that addressed co-occurring substance use and psychiatric 
disorders were also more successful at achieving tobacco cessation than interventions that 
did not address these comorbidities (Moscou-Jackson et al., 2014).  
 Future studies should also aim at assessing substance use and smoking cessation 
interventions that incorporate depression screening and treatment. Depression could be 
the underlying factor impeding successful treatment of co-occurring substance use and 
tobacco use. The treatment of depression could increase the overall well-being of persons 
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living with HIV, as well as having an effect on the reduction of substance or cigarette 
smoking behaviors.  
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Table 1. Demographic characteristics among adults with major depression and without major depression 
 Major Depression 
 
Without Major Depression Total MMP Participants 
 N* Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI* 
Gender          
Male 29  977 6.88% 
(4.63%-9.12%) 
392 13,224 93.12% 
(90.88%-95.37%) 
421 14,201 70.20% 
(64.46%-75.93%) 
Female 22 893 15.21% 
(8.78%-21.64%) 
144 4,977 84.79% 
(78.36%-91.22%) 
166 5,870 29.02% 
(23.58%-34.46%) 
Transgender** 0 --- --- 4 159 --- 4 159 --- 
Sexual Orientation          
Homosexual, gay, or lesbian 14 483 6.11% 
(3.03%-9.18%) 
220 7,421 93.89% 
(90.82%-96.97%) 
234 7,903 39.27% 
(31.28%-47.26%) 
Bisexual  6 188 8.30% 
(2.16%-14.43%) 
60 
 
2,076 
 
91.70% 
(85.57%-97.84%) 
66 2,264 11.25% 
(8.96%-13.54%) 
Heterosexual  29 1,150 11.94% 
(7.76%-16.11%) 
252 8,483 88.06% 
(83.89%-92.24%) 
281 9,633 47.86% 
(41.58%-54.14%) 
Other** 2 50 --- 5 276 --- 7 326 --- 
Race/Ethnicity          
Alaskan Native/American Indian** 0 --- --- 2 77 --- 2 77 --- 
Asian**  0 --- --- 2 78 --- 2 78 --- 
Black/African American 28 1,054 7.87% 
(4.56%-11.17%) 
365 12,346 92.13% 
(88.83%-95.44%) 
393 13,400 66.37% 
(61.81%-70.93%) 
White/Caucasian  16 589 12.93% 
(8.13%-17.73%) 
121 3,967 87.07% 
(82.27%-91.87%) 
137 4,556 22.57% 
(17.82%-27.31%) 
Multi-Racial 6 190 10.20% 
(2.40%-18.00%) 
45 1,674 89.80% 
(82.00%-97.60%) 
51 1,864 9.24% 
(6.33%-12.13%) 
Hispanic/Latino** 1 36 --- 4 177 --- 5 213 --- 
Age          
18-24** 6 233 --- 30 1,137 82.95% 
(70.67%-95.24%) 
36 1,371 6.78% 
(4.68%-8.87%) 
25-34** 9 271 --- 70 2,374 89.76% 
(81.73%-97.80%) 
79 2,645 13.07% 
(10.34%-15.81%) 
35-44** 7 305 --- 162 5,675 94.89% 
(90.52%-99.26%) 
169 5,980 29.56% 
(25.91%-33.22%) 
45-54 23 872 12.90% 
(8.01%-17.79%) 
174 5,892 87.10% 
(82.21%-91.99%) 
197 6,764 33.44% 
(30.17%-36.70%) 
>  55** 6 187 --- 102 3,189 94.46% 
(90.11%-98.80%) 
108 3,376 16.69% 
(14.02%-19.36%) 
Education          
High School/GED 30 1,148 13.04% 
(8.24%-17.85%) 
225 7,656 86.96% 
(82.15%-91.76%) 
255 8,804 43.52% 
(36.33%-50.71%) 
Some college 15 524 7.05% 200 6,907 92.95% 215 7,431 36.73% 
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(3.31%-10.79%) (89.21%-96.69%) (32.35%-41.12%) 
Bachelor’s Degree** 4 142 --- 77 2,566 94.76% 
(89.92%-99.60%) 
81 2,708 13.39% 
(9.30%-17.47%) 
Post-graduate studies** 2 56 --- 38 1,230 95.67% 
(89.51%-100%) 
40 1,286 6.36% 
(3.72%-8.99%) 
Total 51 1,870 9.24% 
(6.78%-11.70%) 
540 18,360 90.76% 
(88.30%-93.22%) 
591 20,230 100% 
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size. 
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.  
***Column percentages reported for total MMP participant column, whereas row percentages are reported for characteristics comparing major depression and no major depression.  
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Table 2. Associations of major depression with dependent variables 
 Row percent 
Unadjusted 
OR** 
P-
Value 
Adjusted 
OR*** 
P-
Value 
Dependent Variables      
Medication Non-Adherence 
         No Major depression 
         Major Depression 
 
8.45% (6.0, 10.9) 
21.3% (9.6, 33.1) 
1.00 Referent 
3.01 (1.26, 7.18) 0.01* 
1.00 Referent 
2.52 (1.20, 5.28) 0.01* 
Current smoker 
         No Major Depression 
         Major Depression 
32.3% (27.6, 37.0) 
62.4% (46.3, 78.4) 
1.00 Referent 
3.48 (1.75, 6.91) 0.0004* 
1.00 Referent 
3.04 (1.48, 6.23) 0.003* 
Non-injection Drug Use 
         No Major Depression 
         Major Depression 
22.3% (18.0, 26.5) 
36..1% (21.8, 50.5) 
1.00 Referent 
1.98 (1.06, 3.70) 0.03* 
1.00 Referent 
2.17 (1.10, 4.25) 0.03* 
Injection Drug Use**** 
         No Major Depression 
         Major Depression 
--- 
--- 
1.00 Referent 
3.99 (1.06, 14.99) 0.04* 
1.00 Referent 
5.62 (0.96, 32.81) 0.06 
*Significant values at P<0.05. 
**Unadjusted OR obtained from bivariate analyses.  
***Adjusted based upon bivariate analyses and the presence of confounders in the literature among noted variables. Medication 
adherence was adjusted for gender. Current cigarette smoking, non-injection drug use, and injection drug use were adjusted for age, 
gender, race, and education. 
****Percentages suppressed if coefficient of variation >30%.  
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Table 3.a. Demographics among adults reporting adherence to ART medication and persons reporting non-adherence to ART medication 
 Adherence to ART medication 
 
Non-adherence to ART 
medication 
Total MMP Participants 
 N* Weighted N Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
N Weighted N Percentage 
(95% CI) 
Gender          
Male 385 12,912 72.56% 
(67.29%-77.83%) 
27 889 46.55% 
(28.69%-64.41%) 
412 13,802 70.04% 
(64.46%-75.61%) 
Female 134 4,764 26.88% 
(21.67%-31.88%) 
28 981 51.35% 
(33.28%-69.42%) 
162 5,745 29.16% 
(23.86%-34.45%) 
Transgender** 3 119 --- 1 40 --- 4 159 --- 
Sexual Orientation          
Homosexual, gay, or lesbian 211 7,103 40.26% 
(32.75%-47.78%) 
16 536 28.06% 
(14.09%-42.03%) 
227 7,639 39.07% 
(31.46%-46.68%) 
Bisexual**  55 1,832 10.39% 
(7.77%-13.01%) 
7 254 --- 62 2,087 10.67% 
(8.19%-13.16%) 
Heterosexual  248 8,502 48.20% 
(41.65%-54.74%) 
32 1,097 57.41% 
(43.55%-71.27%) 
280 9,599 49.10% 
(42.86%-55.33%) 
Other** 4 203 --- 1 23 --- 5 226 --- 
Race/Ethnicity          
American Indian/Alaskan Native** 1 31 --- 0 --- --- 1 31 --- 
Asian** 2 78 --- 0 --- --- 2 78 --- 
African American 344 11,711 66.16% 
(60.65%-71.67%) 
41 1,381 72.30% 
(52.55%-92.06%) 
385 13,093 66.76% 
(61.97%-71.55%) 
White 124 4,094 23.13% 
(18.10%-28.16%) 
10 318 16.66% 
(7.64%-25.69%) 
134 4,413 22.50% 
(17.60%-27.41%) 
Multi-Racial** 44 1,572 8.88% 
(6.01%-11.75%) 
5 211 --- 49 1,783 9.09% 
(6.09%-12.09%) 
Hispanic/Latino** 5 213 --- 0 --- --- 5 213 --- 
Age          
18-24 29 1,110 6.24% 
(4.06%-8.41%) 
4 132 --- 33 1,242 6.30% 
(4.24%-8.37%) 
25-34 66 2,218 12.47% 
(9.59%-15.34%) 
8 276 --- 74 2,495 12.66% 
(9.80%-15.51%) 
35-44 142 4,888 27.47% 
(24.00%-30.93%) 
17 615 32.21% 
(19.34%-45.09%) 
159 5,503 27.93% 
(24.53%-31.33%) 
45-54 176 6,137 34.49% 
(30.77%-38.20%) 
20 640 33.51% 
(21.57%-45.45%) 
196 6,777 34.39% 
(31.08%-37.71%) 
>  55 109 3,442 19.34% 
(16.08%-22.60%) 
6 176 --- 115 3,618 18.36% 
(15.44%-21.28%) 
Education          
High School/GED 231 8,019 45.06% 
(35.51%-54.62%) 
24 835 43.68% 
(30.88%-56.49%) 
255 8,854 44.93% 
(36.60%-53.26%) 
Some college 186 6,406 36.00% 20 656 34.33% 206 7,062 35.84% 
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(29.50%-42.50%) (20.13%-48.53%) (30.45%-41.22%) 
Bachelor’s Degree** 72 2,371 13.32% 
(9.44%-17.20%) 
8 284 --- 80 2,655 13.47% 
(9.47%-17.48%) 
Post-graduate studies** 33 999 5.62% 
(3.60%-7.63%) 
4 136 --- 37 1,136 5.76% 
(3.76%-7.77%) 
Major Depression           
Yes 38 1,417 8.21% 
(5.83%-10.59%) 
11 385 20.82% 
(8.84%-32.80%) 
49 1,802 9.24% 
(6.78%-11.70%) 
No 470 15,840 91.79% 
(89.41%-94.17%) 
43 1,463 79.18% 
(67.20%-91.16%) 
513 18,360 90.76% 
(88.30%-93.22%) 
Total 508 17,258 90.33% 
(87.75%-92.91%) 
54 1,847 9.67% 
(7.09%-12.25%) 
562 19,105 100% 
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size. 
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.  
***Column percentages reported  
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Table 3.b. Demographics among adults who used injection drugs in the past 12 months and persons who did not use injection drugs in the 
past 12 months 
 Injection Drug Use in the Past 
12 Months** 
 
No Injection Drug Use in the 
Past 12 Months 
Total MMP Participants 
 N* Weighted 
N 
Percentage 
(95% CI) 
N Weighted N Percentage 
(95% CI) 
N Weighted N Percentage 
(95% CI* 
Gender          
Male 7 238 --- 424 14,354 69.69% 
(63.89%-75.49%) 
431 14,592 69.91% 
(64.00%-75.83%) 
Female 1 36 --- 172 6,085 29.54% 
(24.04%-35.04%) 
173 6,121 29.33% 
(23.72%-34.92%) 
Transgender 0 0 --- 4 159 --- 4 159 --- 
Sexual Orientation          
Homosexual, gay, or lesbian 6 206 --- 231 7,819 38.25% 
(30.52%-45.98%) 
237 8,025 38.74% 
(30.81%-46.67%) 
Bisexual 1 36 --- 66 2,276 11.14% 
(8.75%-13.52%) 
67 2,313 11.16% 
(8.81%-13.52%) 
Heterosexual 1 32 --- 292 10,021 49.02% 
(42.62%-55.42%) 
293 10,053 48.52% 
(42.12%-54.93%) 
Other 0 --- --- 7 325 --- 7 325 --- 
Race/Ethnicity          
Alaskan Native/American Indian 0 --- --- 2 77 --- 2 77 --- 
Asian 1 49 --- 1 29 --- 2 78 --- 
African American 0 --- --- 408 13,950 68.04% 
(63.51%-72.57%) 
408 13,950 67.14% 
(62.48%-71.81%) 
White 6 189 --- 132 4,404 21.48% 
(16.77%-26.20%) 
138 4,593 22.11% 
(17.33%-26.89%) 
Multi-Racial 1 36 --- 50 1,828 8.92% 
(6.19%-11.65%) 
51 1,864 8.97% 
(6.17%-11.78%) 
Hispanic/Latino 0 --- --- 5 213 --- 5 213 --- 
Age          
18-24 1 49 --- 36 1,362 6.61% 
(4.53%-8.70%) 
37 1,411 6.76% 
(4.71%-8.81%) 
25-34 2 68 --- 79 2,665 12.94% 
(10.47%-15.41%) 
81 2,733 13.10% 
(10.51%-15.68%) 
35-44 2 52 --- 169 5,976 29.01% 
(25.40%-32.63%) 
171 6,028 28.88% 
(25.38%-32.38%) 
45-54 3 105 --- 197 6,800 33.01% 
(29.73%-36.30%) 
200 6,905 33.08% 
(29.78%-36.39%) 
>  55 0 --- --- 117 3,701 17.97% 
(15.18%-20.75%) 
117 3,701 17.73% 
(14.94%-20.52%) 
Education          
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High School/GED 1 32 --- 266 9,228 44.80% 
(37.26%-52.33%) 
267 9,259 44.36% 
(36.91%-51.82%) 
Some college 5 152 --- 213 7,401 35.93% 
(31.24%-40.63%) 
218 7,553 36.19% 
(31.65%-40.73%) 
Bachelor’s Degree 2 90 --- 81 2,683 13.03% 
(9.10%-16.95%) 
83 2,773 13.29% 
(9.23%-17.34%) 
Post-graduate studies 0 --- --- 40 1,286 6.24% 
(3.62%-8.87%) 
40 1,286 6.16% 
(3.58%-8.74%) 
Major Depression           
Yes 2 77 --- 49 1,792 8.98% 
(6.45%-11.51%) 
51 1,870 9.24% 
(6.78%-11.70%) 
No 6 197 --- 534 18,163 91.02% 
(88.49%-93.55%) 
540 18,360 90.76% 
(88.30%-93.22%) 
Total 8 274 --- 600 20,597 98.69% 
(97.65%-99.72%) 
608 20,871 100% 
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size. 
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.  
***Row percentages reported  
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Table 3.c. Demographics among adults who used non-injection drugs in the past 12 months and persons who did not use non-injection 
drugs in the past 12 months 
 Non-Injection Drug Use in the 
Past 12 Months 
 
No Non-Injection Drug Use in 
the Past 12 Months 
Total MMP Participants 
 N* Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
N Weighted N Percentage 
(95% CI) 
Gender          
Male 111 3,880 80.66% 
(72.83%-88.49%) 
320 10,712 66.70% 
(60.45%-72.94%) 
431 14,592 69.91% 
(64.00%-75.83%) 
Female 25 885 18.39% 
(10.83%-25.95%) 
148 5,236 32.60% 
(26.70%-38.50%) 
173 6,121 29.33% 
(23.72%-34.92%) 
Transgender** 2 46 --- 2 113 --- 4 159 --- 
Sexual Orientation          
Homosexual, gay, or lesbian 72 2,462 52.04% 
(27.80%-41.81%) 
165 5,563 32.21% 
(27.80%-41.81%) 
237 8,025 38.74% 
(30.81%-46.67%) 
Bisexual**  14 486 --- 53 1,827 11.43% 
(8.76%-14.10%) 
67 2,313 11.16% 
(8.81%-13.52%) 
Heterosexual  49 1,711 36.16% 
(24.76%-47.56%) 
244 8,342 52.19% 
(46.23%-58.14%) 
293 10,053 48.52% 
(42.12%-54.93%) 
Other** 1 73 --- 6 252 --- 7 325 --- 
Race/Ethnicity          
American Indian/Alaskan Native** 0 0 --- 2 77 --- 2 77 --- 
Asian** 1 49 --- 1 29 --- 2 78 --- 
African American 84 2,995 62.77% 
(51.90%-73.65%) 
324 10,956 68.45% 
(63.96%-72.93%) 
408 13,950 67.14% 
(62.48%-71.81%) 
White 41 1,425 29.87% 
(18.25%-41.50%) 
97 3,168 19.79% 
(15.75%-23.83%) 
138 4,593 22.11% 
(17.33%-26.89%) 
Multi-Racial 11 302 --- 40 1,562 9.76% 
(6.44%-10.09%) 
51 1,864 8.97% 
(6.17%-11.78%) 
Hispanic/Latino** 0 --- --- 5 213 1--- 5 213 --- 
Age          
18-24 18 575 11.96% 
(6.96%-16.97%) 
19 836 5.20% 
(3.10%-7.31%) 
37 1,411 6.76% 
(4.71%-8.81%) 
25-34 22 760 15.79% 
(9.13%-22.45%) 
59 1,974 12.29% 
(9.53%-15.04%) 
81 2,733 13.10% 
(10.51%-15.68%) 
35-44 42 1,444 30.01% 
(20.89%-39.13%) 
129 4.584 28.54% 
(24.42%-32.67%) 
171 6,028 28.88% 
(25.38%-32.38%) 
45-54 40 1,546 32.13% 
(23.18%-41.08%) 
160 5,360 33.37% 
(29.54%-37.21%) 
200 6,905 33.08% 
(29.78%-36.39%) 
>  55** 16 486 --- 101 3,214 20.01% 
(17.03%-22.99%) 
117 3,701 17.73% 
(14.94%-20.52%) 
Education          
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High School/GED 61 2,066 42.95% 
(31.60%-54.31%) 
206 7,193 44.79% 
(37.31%-52.26%) 
267 9,259 44.36% 
(36.91%-51.82%) 
Some college 52 1,874 38.96% 
(28.39%-49.53%) 
166 5,679 35.36% 
(30.13%-40.59%) 
218 7,553 36.19% 
(31.65%-40.73%) 
Bachelor’s Degree 17 561 11.66% 
(5.81%-17.50%) 
66 2,212 13.77% 
(9.33%-18.21%) 
83 2,773 13.29% 
(9.23%-17.34%) 
Post-graduate studies 8 309 --- 32 977 6.08% 
(3.61%-8.55%) 
40 1,286 6.16% 
(3.58%-8.74%) 
Major Depression           
Yes 18 676 14.19% 
(8.26%-20.12%) 
33 1,194 7.72% 
(4.98%-10.46%) 
51 1,870 9.24% 
(6.78%-11.70%) 
No 119 4,086 85.81% 
(79.88%-91.74%) 
421 14,273 92.28% 
(89.54%-95.02% 
540 18,360 90.76% 
(88.30%-93.22%) 
Total 138 4,811 23.05% 
(18.93%-27.17%) 
470 16,601 76.95% 
(72.83%-81.07%) 
608 20,871 100% 
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size. 
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.  
***Column percentages reported  
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Table 3.d. Demographics among current smokers, former smokers, and never-smokers 
 Current Smokers Former Smokers Never-Smokers Total MMP Participants 
 N Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
N Weighted 
N 
Percentage 
(95% CI) 
Gender             
Male 151 5,082 68.02% 
(58.55%-77.48%) 
87 2,934 68.96% 
(58.97%-78.95%) 
192 6,551 72.23% 
(65.82%-78.65%) 
430 14,567 70.05% 
(64.28%-75.82%) 
Female 61 2,344 31.37% 
(21.84%-40.90%) 
39 1,321 31.04% 
(21.05%-41.03%) 
72 2,405 26.52% 
(19.72%-33.32%) 
172 6,070 29.19% 
(23.71%-34.67%) 
Transgender** 2 46 --- 0 --- --- 0 113 --- 4 159 --- 
Sexual Orientation             
Homosexual, gay, or 
lesbian 
79 2,706 36.21% 
(23.89%-45.53%) 
40 1,437 34.39% 
(23.10%-45.68%) 
118 3,883 43.19% 
(36.65%-49.73%) 
237 8,025 38.88% 
(31.05%-46.71%) 
Bisexual  21 643 8.61% 
(4.42%-12.80%) 
18 600 14.36% 
(8.36%-20.37%) 
27 1,044 11.62% 
(8.04%-15.19%) 
66 2,288 11.08% 
(8.71%-13.45%) 
Heterosexual  113 4,099 54.87% 
(42.88%-66.85%) 
65 2,069 49.50% 
(39.24%-59.77%) 
114 3,833 42.64% 
(36.44%-48.84%) 
292 10,002 48.46% 
(42.18%-54.73%) 
Other** 1 23 --- 1 73 --- 5 229 --- 7 325 --- 
Race/Ethnicity             
American Indian/ 
Alaskan Native** 
0 --- --- 1 46 --- 1 31 --- 2 77 --- 
Asian** 0 --- --- 1 29 --- 1 48 --- 2 78 --- 
African American 132 4,652 62.26% 
(55.18%-69.34%) 
79 2,639 62.60% 
(52.64%-72.57%) 
195 6,584 73.04% 
(67.39%-78.68%) 
406 13,875 67.02% 
(62.38%-71.67%) 
White 56 1,898 25.40% 
(18.45%-32.35%) 
33 1,098 26.05% 
(17.35%-34.75%) 
49 1,598 17.72% 
(12.29%-23.16%) 
138 4,593 22.19% 
(17.44%-26.94%) 
Multi-Racial** 23 796 10.65% 
(6.07%-15.23%) 
11 403 --- 17 666 7.38% 
(3.06%-11.71%) 
51 1,864 9.01% 
(6.17%-11.84%) 
Hispanic/Latino** 3 126 --- 0 --- --- 2 87 --- 
 
5 213 1.03% 
(0.31%-1.75%) 
Age             
18-24** 12 408 --- 3 154 --- 22 849 9.36% 
(5.92%-12.80%) 
37 1,411 6.79% 
(4.73%-8.84%) 
25-34** 34 1,298 17.37% 
(11.74%-23.00%) 
1 19 --- 46 1,417 15.62% 
(12.13%-19.11%) 
81 2,733 13.14% 
(10.54%-15.75%) 
35-44 63 2,186 29.25% 
(22.46%-36.05%) 
29 1,117 26.26%  
(18.34%-34.18%) 
79 2,725 30.04% 
(24.29%-35.80%) 
171 6,028 28.98% 
(25.48%-32.50%) 
45-54 75 2,660 35.60% 
(27.06%-44.14%) 
44 1,486 34.93% 
(25.64%-44.23%) 
79 2,683 29.59% 
(23.99%-35.18%) 
198 6,830 32.84% 
(29.50%-36.18%) 
>  55 30 920 12.31% 
(8.62%-16.00%) 
48 1,456 34.23% 
(25.59%-42.87%) 
39 1,324 14.60% 
(10.49%-18.72%) 
117 3,701 17.80% 
(15.00%-20.59%) 
Education             
High School/GED 123 4,366 58.44% 
(50.00%-66.88%) 
50 1,598 37.56% 
(27.47%-47.66%) 
94 3,295 36.33% 
(28.44%-44.21%) 
267 9,259 44.53% 
(36.90%-52.15%) 
Some college 72 2,545 34.06% 
(27.38%-40.75%) 
49 1,722 40.46% 
(33.45%-47.47%) 
95 3,211 35.41% 
(29.09%-41.73%) 
216 7,477 35.96% 
(31.27%-40.64%) 
Bachelor’s Degree 14 409 5.47% 
(2.13%-8.81%) 
20 690 16.22% 
(8.71%-23.72%) 
49 1,674 18.46% 
(13.14%-23.78%) 
83 2,773 13.33% 
(9.30%-17.37%) 
Post-graduate 5 151 --- 7 245 --- 28 890 9.81% 40 1,286 6.18% 
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studies** (4.90%-14.72%) (3.61%-8.76%) 
Major Depression             
Yes** 29 1,166 16.06% 
(11.13%-20.99%) 
6 179 --- 16 524 5.93% 
(2.66%-9.21%) 
51 1,870 9.28% 
(6.80%-11.76%) 
No 180 6,094 83.94% 
(79.01%-88.87%) 
115 3,876 95.58% 
(91.63%-99.52%) 
243 8,314 94.07% 
(90.79%-97.34%) 
538 18,284 90.72% 
(88.24%-93.20%) 
Total 214 7,472 35.93% 
(30.74%-41.12%) 
126 4,255 20.46% 
(16.92%-24.00%) 
266 9,069 43.61% 
(38.27%-48.95%) 
606 20,796 100% 
*Unweighted N totals may not add up consistently due to missing variables. Missing variables were not reported if they comprised less than 10% of the total sample size. 
**Weighted percentages were suppressed if estimates had a coefficient of variance >30%.  
***Row percentages reported  
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Table 3.e. Bivariate associations of major depression with demographic variables 
Demographic Variables Unadjusted Odds Ratio P-Value 
Gender 
   Male 
   Female 
1.00 Referent 
2.09 (1.24, 3.50) 0.006* 
Race 
    White 
    Black/African American 
    Other 
1.00 Referent 
0.58 (0.30, 1.12) 
0.76 (0.27, 2.10) 
0.10 
0.60 
Education 
    High School/GED  
    Post-High School 
1.00 Referent 
0.45 (0.23, 0.87) 0.02* 
Age 0.99 (0.96, 1.02) 0.46 
*Significance at p<0.05 
 
